Home›Paclitaxel Aibumin Bound›Paclitaxel Aibumin Bound + Relacorilant

Does Paclitaxel Aibumin Bound Interact with Relacorilant?

Paclitaxel Aibumin Bound and Relacorilant have a contraindicated drug interaction according to U.S. FDA drug labeling data. Avoid coadministration of relacorilant plus nab-paclitaxel with strong CYP3A inducers. Both are CYP3A substrates; inducers decrease concentrations and may reduce effectiveness. The mechanism involves cyp3a induction decreases relacorilant and paclitaxel concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Contraindicated
Paclitaxel Aibumin Bound Class
Microtubule Inhibitor
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Paclitaxel Aibumin Bound and Relacorilant occurs because cyp3a induction decreases relacorilant and paclitaxel concentrations. Clinically, this means avoid coadministration of relacorilant plus nab-paclitaxel with strong cyp3a inducers. both are cyp3a substrates; inducers decrease concentrations and may reduce effectiveness. Because of the severity of this interaction, these medications are contraindicated — meaning they should not be taken together under any circumstances. If you are currently taking both, contact your healthcare provider immediately to discuss alternatives.

What To Tell Your Doctor or Pharmacist

If you are taking Paclitaxel Aibumin Bound and your doctor is considering prescribing Relacorilant (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Paclitaxel Aibumin Bound(Paclitaxel)+💊 Relacorilant(Lifyorli)

Severity & Interaction Details

⛔
contraindicated
Avoid this combination
FDA labeling lists this pair as contraindicated. The risk outweighs the benefit in nearly all cases.
Severity scale
MinorContra
On record
Yes
Drug A class
Microtubule Inhibitor
Drug B class
—
Source
NLP:relacorilant

What this means in plain English

Avoid coadministration of relacorilant plus nab-paclitaxel with strong CYP3A inducers. Both are CYP3A substrates; inducers decrease concentrations and may reduce effectiveness.

About Paclitaxel Aibumin Bound and Relacorilant

Paclitaxel Aibumin Bound is a Microtubule Inhibitor. Relacorilant is also sold under the brand name Lifyorli. Paclitaxel Aibumin Bound is given by intravenous (IV) infusion. Paclitaxel Aibumin Bound additionally carries an FDA boxed warning, the FDA's strongest safety alert.

What the FDA label says

"CYP3A induction decreases relacorilant and paclitaxel concentrations"

📖 Source: NLP:relacorilant

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Paclitaxel Aibumin Bound and Relacorilant against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.